Allstate Corp Makes New $775,000 Investment in Natera, Inc. $NTRA

Allstate Corp purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,816 shares of the medical research company’s stock, valued at approximately $775,000.

A number of other institutional investors and hedge funds have also made changes to their positions in NTRA. Hilltop National Bank acquired a new stake in Natera in the 2nd quarter valued at approximately $33,000. Sound Income Strategies LLC boosted its position in shares of Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares during the period. Quent Capital LLC acquired a new stake in shares of Natera in the third quarter valued at $46,000. V Square Quantitative Management LLC purchased a new stake in shares of Natera in the 2nd quarter valued at $53,000. Finally, N.E.W. Advisory Services LLC raised its holdings in shares of Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after buying an additional 226 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Guggenheim upped their target price on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Finally, UBS Group raised their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $245.50.

Natera Price Performance

Shares of NASDAQ NTRA opened at $242.91 on Friday. The business has a 50-day moving average of $233.44 and a two-hundred day moving average of $190.60. The company has a market capitalization of $33.60 billion, a price-to-earnings ratio of -106.07 and a beta of 1.62. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same period last year, the company earned ($0.26) earnings per share. The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. As a group, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Herm Rosenman sold 48,419 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $227.42, for a total value of $11,011,448.98. Following the transaction, the director directly owned 20,342 shares of the company’s stock, valued at $4,626,177.64. This trade represents a 70.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 160,703 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the completion of the sale, the chief executive officer directly owned 144,816 shares of the company’s stock, valued at approximately $28,957,407.36. This trade represents a 52.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 514,562 shares of company stock worth $114,292,421. 5.63% of the stock is currently owned by company insiders.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology — a data milestone that strengthens clinical credibility and could accelerate adoption of a high‑value diagnostic product. Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
• Negative Sentiment: CEO Steven Leonard Chapman sold a material block of shares (71,932 shares on Jan 20 and additional smaller sales on Jan 21), reducing his stake by roughly 24.9% from prior levels — a large, high‑profile insider sale that may be viewed negatively by the market. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy disclosed substantial sales (23,948 and 37,175 shares across Jan 20–21), cutting his ownership materially (~36.7% decrease on later filing) — another large insider liquidation that can weigh on near‑term sentiment. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold shares on Jan 20–21 (multiple transactions totaling tens of thousands of shares combined), modestly reducing their stakes. These coordinated/clustered sales increase perceived supply risk. Insider Form 4 example

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.